Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865849 | 1.00 | AR (0.60) | ARKDM4EGAAATMALPL | |
| SCHEMBL5865857 | 1.00 | AR (0.60) | ARKDM4EGAAATMALPL | |
| SCHEMBL5865922 | 0.99 | AR (0.62) | ARKDM4EGAAATMALPL | |
| SCHEMBL5865930 | 0.96 | AR (0.58) | ARKDM4EGAAATMALPL | |
| SCHEMBL6105300 | 0.88 | AR (0.53) | ARKDM4EGAAATMTP53 | |
| SCHEMBL6105506 | 0.88 | AR (0.53) | ARKDM4EGAAATMTP53 | |
| SCHEMBL5865853 | 0.88 | AR (0.53) | ARKDM4EGAAHTTL3MBTL1 | |
| SCHEMBL6108419 | 0.87 | AR (0.54) | ARKDM4EGAAATMTP53 | |
| SCHEMBL5865909 | 0.86 | KDM4E (0.67) | ARKDM4EHTTBACE1 | |
| SCHEMBL5865940 | 0.86 | ALDH1A1 (0.61) | ARKDM4EGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064207-B2 | 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives, useful for treating alopecia, acne and oily skin | WARNER LAMBERT COMPANY LLC (US) | 2006-06-20 | — | — | US | claimed |
| EP-1587804-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-10-26 | — | — | EP | claimed |
| US-20050085467-A1 | Androgen receptor antagonists | DU DANIEL Y (US) | 2005-04-21 | — | — | US | claimed |
| WO-2004065379-A1 | ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | claimed |
| US-7064207-B2 | 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives, useful for treating alopecia, acne and oily skin | WARNER LAMBERT COMPANY LLC (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1587804-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050085467-A1 | Androgen receptor antagonists | DU DANIEL Y (US) | 2005-04-21 | — | — | US | disclosed |
| WO-2004065379-A1 | ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085467-A1 | Androgen receptor antagonists | AR, NR5A1, ESRRB | AR 1/4885KDM4E 2570/4885GAA 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.